The promise of clinical pharmacogenomic (PGx) testing in enabling personalized medicine is well described in the literature, and there is accumulated evidence showing the use of specific PGx biomarkers for avoiding severe adverse drug reactions in commonly prescribed medications. A recent example is the determination of PGx variants of dihydropyrimidine dehydrogenase (DPYD) on the metabolism of fluorouracil (5-FU), a drug commonly used to treat solid tumor (https://doi.org/10.1200/JCO.23.01748). Despite the efforts by US FDA to facilitate uptake of PGx by relabeling numerous drugs with PGx markers, its adoption for personalizing commonly prescribed medications has been slow due to lack of widely available validated tests, controversy in clinical practice guidelines, lack of clinician familiarity of complex PGx reports, and uncertainties surrounding reimbursement. In this presentation, we describe our approach to overcoming these barriers by using a preemptive, customized genomic implementation model that utilize validated assays in CLIA laboratory in combination with medical records-embedded decision support to enable clinical delivery of PGx information within high-value clinical settings. The model is flexible and scalable to facilitate the wider adoption of PGx use in personalized medicine.

Faculty/Authors

Kiang-Teck J. Yeo, PhD

Physician Competencies: Patient Care, Medical Knowledge, Professionalism, Interpersonal Skills Communication

CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online Educational Activity

Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME).

Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Review the Faculty Disclosures.
3. Click Go to Course to view an overview of the modules in this course.
4. Click Access to begin the course.
5. Submit the course Evaluation.
6. Enter the maximum number of credits offered and click Claim CME to register credit.

Faculty Disclosure

Technical Considerations

Release Date: 09/06/2024
Review Date:
Expiration Date: 03/06/2025